Opexa Therapeutics

Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a publicly traded biotechnology company developing personalized immunotherapies for the treatment of multiple sclerosis (MS) and other autoimmune diseases such as neuromyelitis optica (NMO). These therapies are based on Opexa's proprietary T-cell technology. The company’s lead therapeutic candidate, Tcelna®, is a personalized T-cell immunotherapy currently in a Phase IIb clinical development program (ABLI-T trial) for the treatment of secondary progressive MS.